Orchestra BioMed Holdings (OBIO) AI Stock Analysis

• Market Cap: $214.57M
• Dividend Yield: N/A
• Average Volume (3M): 184.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.05
• Revenue Growth: 6.46%
• EPS Growth: -14.32%
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 56,464,730
• 10 Day Avg. Volume: 214,860
• 30 Day Avg. Volume: 184,688
• PEG Ratio: -0.20
• Price to Book (P/B): 4.47
• Price to Sales (P/S): 55.83
• P/FCF Ratio: -2.90
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 61.88
• Enterprise Value/Gross Profit: 66.53
• Enterprise Value/Ebitda: -2.33
• 1Y Price Target: $13.40
• Price Target Upside: 252.63% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $3.50 ▼(-7.89% Downside)

The score is held down primarily by weak financial performance (declining revenue, significant losses, and high leverage). This is partly offset by constructive technical momentum (price above key moving averages with positive MACD) and supportive corporate events (cash proceeds and strategic financing/partnership developments). Valuation is a secondary drag given the negative P/E and lack of dividend yield data.

Positive Factors

High gross margins

A 92.66% gross margin signals very efficient device-level economics and low direct COGS. Structurally this provides durable operating leverage: as sales scale, high gross margins can absorb R&D and SG&A, improving the company's path to sustainable profitability over months to years.

Strategic partnerships and capital raised

Nearly $150M of capital plus deeper collaboration with Medtronic strengthen funding runway, trial execution and future commercial channels. These structural partnerships and financing materially lower development and go‑to‑market risk, improving chances to complete pivotal trials and scale device adoption.

Vivasure sale proceeds boost liquidity

Up to $21M in non‑dilutive proceeds, with ~$11M expected in 2026, meaningfully strengthens near‑term liquidity. This structural cash inflow extends runway, funds clinical and development milestones, and validates the partnership‑driven device development model versus needing immediate dilutive financing.

Negative Factors

High leverage

A debt/equity ratio of 6.68 reflects heavy reliance on debt financing, increasing interest burden and refinancing risk. Structurally, high leverage constrains strategic flexibility, raises covenant/default risk, and amplifies downside if cash generation underperforms over the next several quarters.

Declining revenue and persistent losses

A declining revenue trend combined with deep negative net and operating margins indicates the company is not yet scaling a profitable business model. Over a multi‑month horizon, continued top‑line weakness plus negative margins means sustained dependence on external funding until revenue growth or structural cost reductions occur.

Weak operating cash generation

Operating cash flow negative versus net losses shows core operations aren’t producing cash. FCF only marginally covers net losses, so the company remains structurally dependent on external financing or asset monetization to fund trials and commercialization, raising dilution and execution risk.

Orchestra BioMed Holdings Business Overview & Revenue Model

Company Description

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

How the Company Makes Money

Orchestra BioMed generates revenue primarily through the commercialization of its medical devices and therapeutic solutions. The company earns money by selling its proprietary products, such as the Virtue® Sirolimus-Eluting Balloon, to healthcare providers and hospitals. Additionally, OBIO may engage in strategic partnerships with larger healthcare companies to co-develop or market its products, which can also provide financial support through upfront payments, milestone payments, and royalties on future sales. The company focuses on expanding its market reach and enhancing its product offerings, which are significant factors contributing to its earnings potential.

Orchestra BioMed Holdings Financial Statement Overview

Summary

Financials are weak overall: revenue is declining (-4.28% TTM) and profitability is deeply negative (net margin -23.67% with negative EBIT/EBITDA margins). Leverage is high (debt-to-equity 6.68) and ROE is negative, partially offset by a very strong gross margin (92.66%) and slightly improving free cash flow growth (1.83% TTM).

Income Statement

Orchestra BioMed Holdings shows a declining revenue trend with a negative revenue growth rate of -4.28% in TTM. The company has a strong gross profit margin of 92.66%, indicating efficient cost management. However, the net profit margin is significantly negative at -23.67%, reflecting substantial losses. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 6.68 in TTM, indicating high leverage and potential financial risk. The return on equity is negative, suggesting that the company is not generating profit from shareholders' equity. The equity ratio is relatively low, pointing to a reliance on debt financing.

Cash Flow

The cash flow statement shows a slight improvement in free cash flow growth at 1.83% in TTM. However, the operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its net losses. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally covering net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.82M	2.64M	2.76M	3.53M	-782.00K	5.70M
Gross Profit	2.62M	2.43M	2.57M	3.21M	-981.00K	5.56M
EBITDA	-74.74M	-63.99M	-51.22M	-32.44M	-21.62M	-18.61M
Net Income	-75.10M	-61.02M	-49.12M	-33.61M	-23.01M	-21.36M
Balance Sheet
Total Assets	104.81M	76.17M	95.21M	95.57M	13.53M	38.09M
Cash, Cash Equivalents and Short-Term Investments	95.82M	66.81M	87.59M	83.78M	10.90M	35.79M
Total Debt	1.83M	16.53M	1.69M	11.87M	5.67M	9.46M
Total Liabilities	61.07M	43.22M	27.17M	43.04M	84.76M	86.63M
Stockholders Equity	43.74M	32.96M	68.04M	52.53M	-71.23M	-48.54M
Cash Flow
Free Cash Flow	-60.79M	-50.85M	-46.20M	-29.88M	-19.70M	-26.72M
Operating Cash Flow	-60.23M	-50.56M	-46.13M	-29.29M	-19.43M	-26.18M
Investing Cash Flow	-12.98M	13.09M	10.69M	-64.12M	13.02M	26.97M
Financing Cash Flow	89.62M	29.17M	46.22M	103.26M	-3.99M	10.00M

Orchestra BioMed Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBIO, the sentiment is Negative. The current price of 3.8 is below the 20-day moving average (MA) of 4.18, below the 50-day MA of 4.39, and above the 200-day MA of 3.37, indicating a neutral trend. The MACD of -0.14 indicates Positive momentum. The RSI at 42.99 is Neutral, neither overbought nor oversold. The STOCH value of 55.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OBIO.

Orchestra BioMed Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLYM	60 Neutral	$344.33M	-6.73	-25.65%	―	―	64.81%
OBIO	52 Neutral	$214.57M	-2.09	-166.97%	―	6.46%	-14.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CGTX	47 Neutral	$90.92M	-2.17	-109.73%	―	―	50.39%
PYXS	45 Neutral	$94.02M	-0.95	-87.28%	―	-82.53%	-52.00%
CRDF	44 Neutral	$106.43M	-1.99	-102.71%	―	-27.29%	16.40%

Orchestra BioMed Holdings Corporate Events

Orchestra BioMed gains cash from Vivasure sale proceeds

On January 12, 2026, Orchestra BioMed announced it expects to receive up to $21 million in cash proceeds following the January 9, 2026 closing of Haemonetics Corporation’s acquisition of its long-held strategic investment Vivasure Medical, an Ireland-based developer of bioabsorbable, large-bore percutaneous vessel closure technology. Orchestra BioMed anticipates $11 million of this amount will be realized in 2026 through an upfront payment of about $5 million and a first milestone payment of about $6 million, with additional consideration tied to future revenue earnouts, underscoring the financial value and strategic validation of its partnership-driven device development model and strengthening its position as an innovation partner to larger medtech players.

The most recent analyst rating on (OBIO) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.

Orchestra BioMed Secures FDA Breakthrough Designation

On November 12, 2025, Orchestra BioMed Holdings held a conference call to discuss significant business updates, including clinical, strategic, and financing developments. The company highlighted its recent achievements, such as raising nearly $150 million in capital, strengthening collaborations with Medtronic, and securing FDA Breakthrough Device Designation for AVIM Therapy. These developments position Orchestra BioMed optimally to complete pivotal trials and advance its therapies towards regulatory approvals, enhancing its market position and potential profitability.

The most recent analyst rating on (OBIO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.